Definium Therapeutics (DFTX) Free Cash Flow (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Free Cash Flow data on file, last reported at -$42.5 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 44.46% year-over-year to -$42.5 million in Q1 2026; TTM through Mar 2026 was -$144.6 million, a 57.23% decrease from a year earlier, with the FY2025 full-year figure at -$131.5 million, down 66.32% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$42.5 million, up from -$43.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for DFTX reached as high as -$9.3 million in Q3 2022 and fell as low as -$43.0 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$21.6 million across 5 years, with a median of -$17.2 million in 2024.
• Across the five-year window, Free Cash Flow soared 44.6% in 2022 and plunged 78.56% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$12.8 million in 2022, then plunged by 60.11% to -$20.6 million in 2023, then slipped by 23.56% to -$25.4 million in 2024, then slumped by 69.01% to -$43.0 million in 2025, then climbed by 1.04% to -$42.5 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$42.5 million in Q1 2026, -$43.0 million in Q4 2025, and -$29.6 million in Q3 2025.